title: Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST.
abstract: OBJECTIVE
  The purpose of this article is to review cancer- and therapy-specific tumor response assessment criteria used in clinical trials and in practice, with illustrative case examples, and to discuss future directions toward "personalized" tumor response assessment.
  
  
  CONCLUSIONS
  Although Response Evaluation Criteria in Solid Tumors will remain as the primary generalized criteria for response assessment, newer cancer- and therapy-specific criteria will play an important role in providing state-of-the-art response assessment of tumor following molecular targeted therapy and will contribute to personalized cancer care in the era of molecular medicine.
authors.affiliation: Department of Imaging, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Mizuki_Nishino@dfci.harvard.edu
authors.forename: Mizuki
authors.initials: M
authors.lastname: Nishino
authors.forename: Jyothi P
authors.initials: JP
authors.lastname: Jagannathan
authors.forename: Katherine M
authors.initials: KM
authors.lastname: Krajewski
authors.forename: Kevin
authors.initials: K
authors.lastname: O'Regan
authors.forename: Hiroto
authors.initials: H
authors.lastname: Hatabu
authors.forename: Geoffrey
authors.initials: G
authors.lastname: Shapiro
authors.forename: Nikhil H
authors.initials: NH
authors.lastname: Ramaiya
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology*; D002986:Clinical Trials as Topic; D003952:Diagnostic Imaging; D018450:Disease Progression; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology*; D058990:Molecular Targeted Therapy / Q000639:trends*; D017063:Outcome Assessment, Health Care / Q000592:standards*; D057285:Precision Medicine; D011237:Predictive Value of Tests; D011379:Prognosis
chemical_list: D020533:Angiogenesis Inhibitors